Successful Withdrawal of Long-term Epoprostenol Therapy for Pulmonary Arterial Hypertension
- 1 October 2003
- Vol. 124 (4) , 1612-1615
- https://doi.org/10.1016/s0012-3692(16)48713-1
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Survival in Primary Pulmonary HypertensionCirculation, 2002
- Long-term intravenous epoprostenol infusion in primary pulmonary hypertensionJournal of the American College of Cardiology, 2002
- Differential Effects of Stable Prostacyclin Analogs on Smooth Muscle Proliferation and Cyclic AMP Generation in Human Pulmonary ArteryAmerican Journal of Respiratory Cell and Molecular Biology, 2002
- Flolan Infusion Interruption: A Lethal Complication during Venous AccessJournal of Vascular and Interventional Radiology, 2001
- Pulmonary HypertensionJAMA, 2000
- Increased Plasma P-Selectin and Decreased Thrombomodulin in Pulmonary Arterial Hypertension Were Improved by Continuous Prostacyclin TherapyCirculation, 2000
- Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of DiseaseAnnals of Internal Medicine, 2000
- Reduction in Pulmonary Vascular Resistance with Long-Term Epoprostenol (Prostacyclin) Therapy in Primary Pulmonary HypertensionNew England Journal of Medicine, 1998
- Primary Pulmonary HypertensionNew England Journal of Medicine, 1997
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996